Next Article in Journal
Treatment Resistance Mechanisms of Malignant Glioma Tumor Stem Cells
Next Article in Special Issue
Role of p53 in Cell Death and Human Cancers
Previous Article in Journal
Experimental Animal Models of Pancreatic Carcinogenesis for Prevention Studies and Their Relevance to Human Disease
Previous Article in Special Issue
Protein Kinase C: An Attractive Target for Cancer Therapy
Cancers 2011, 3(1), 603-620; doi:10.3390/cancers3010603
Review

Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer

1
, 2
 and 1,2,*
Received: 29 December 2010; in revised form: 28 January 2011 / Accepted: 30 January 2011 / Published: 10 February 2011
(This article belongs to the Special Issue Cell Death and Cancer)
View Full-Text   |   Download PDF [270 KB, uploaded 10 February 2011]   |   Browse Figure
Abstract: Numerous biologic approaches are being investigated as anti-cancer therapies in an attempt to induce tumor regression while circumventing the toxic side effects associated with standard chemo- or radiotherapies. Among these, tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) has shown particular promise in pre-clinical and early clinical trials, due to its preferential ability to induce apoptotic cell death in cancer cells and its minimal toxicity. One limitation of TRAIL use is the fact that many tumor types display an inherent resistance to TRAIL-induced apoptosis. To circumvent this problem, researchers have explored a number of strategies to optimize TRAIL delivery and to improve its efficacy via co-administration with other anti-cancer agents. In this review, we will focus on TRAIL-based gene therapy approaches for the treatment of malignancies. We will discuss the main viral vectors that are being used for TRAIL gene therapy and the strategies that are currently being attempted to improve the efficacy of TRAIL as an anti-cancer therapeutic.
Keywords: TRAIL; gene therapy; viral vectors; cancer; apoptosis TRAIL; gene therapy; viral vectors; cancer; apoptosis
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Norian, L.A.; James, B.R.; Griffith, T.S. Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer. Cancers 2011, 3, 603-620.

AMA Style

Norian LA, James BR, Griffith TS. Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer. Cancers. 2011; 3(1):603-620.

Chicago/Turabian Style

Norian, Lyse A.; James, Britnie R.; Griffith, Thomas S. 2011. "Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer." Cancers 3, no. 1: 603-620.


Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert